2O9.F RENALYTIX PLC LS-0025

Healthcare Health Care Technology Frankfurt Exchange
0.0620 EUR
Close of Nov 11, 2026
0.0110 0.0775
Market cap
EUR 41.6M
P/E
-
P/B
7.86x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is 2O9.F undervalued?

Graham number

The Graham number of RENALYTIX PLC LS-0025 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RENALYTIX PLC LS-0025 fundamental analysis

No fundamental analysis for RENALYTIX PLC LS-0025 yet.

RENALYTIX PLC LS-0025 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RENALYTIX PLC LS-0025

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. The co…

Full company profile